A detailed history of Krensavage Asset Management, LLC transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Krensavage Asset Management, LLC holds 1,498,074 shares of ENTA stock, worth $13.6 Million. This represents 8.7% of its overall portfolio holdings.

Number of Shares
1,498,074
Previous 1,251,338 19.72%
Holding current value
$13.6 Million
Previous $16.2 Million 4.37%
% of portfolio
8.7%
Previous 7.45%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.05 - $16.54 $2.48 Million - $4.08 Million
246,736 Added 19.72%
1,498,074 $15.5 Million
Q2 2024

Aug 14, 2024

BUY
$11.43 - $17.02 $1.45 Million - $2.16 Million
126,752 Added 11.27%
1,251,338 $16.2 Million
Q1 2024

May 15, 2024

BUY
$10.08 - $17.46 $3.85 Million - $6.67 Million
381,762 Added 51.39%
1,124,586 $19.6 Million
Q4 2023

Feb 14, 2024

BUY
$8.18 - $10.78 $63,157 - $83,232
7,721 Added 1.05%
742,824 $6.99 Million
Q3 2023

Nov 14, 2023

BUY
$11.09 - $22.13 $526,664 - $1.05 Million
47,490 Added 6.91%
735,103 $8.21 Million
Q2 2023

Aug 11, 2023

BUY
$20.68 - $39.85 $1.74 Million - $3.36 Million
84,312 Added 13.98%
687,613 $14.7 Million
Q1 2023

May 15, 2023

BUY
$38.82 - $54.59 $329,310 - $463,086
8,483 Added 1.43%
603,301 $24.4 Million
Q4 2022

Feb 15, 2023

BUY
$40.77 - $53.73 $222,522 - $293,258
5,458 Added 0.93%
594,818 $27.7 Million
Q3 2022

Nov 14, 2022

SELL
$48.29 - $71.27 $1.71 Million - $2.52 Million
-35,408 Reduced 5.67%
589,360 $30.6 Million
Q2 2022

Aug 16, 2022

BUY
$38.13 - $76.93 $2.9 Million - $5.84 Million
75,940 Added 13.84%
624,768 $29.5 Million
Q1 2022

May 17, 2022

SELL
$56.06 - $74.11 $856,260 - $1.13 Million
-15,274 Reduced 2.71%
548,828 $39.1 Million
Q4 2021

Feb 15, 2022

SELL
$60.19 - $97.37 $22.4 Million - $36.3 Million
-372,675 Reduced 39.78%
564,102 $42.2 Million
Q3 2021

Nov 16, 2021

SELL
$41.02 - $58.65 $117,850 - $168,501
-2,873 Reduced 0.31%
936,777 $53.2 Million
Q2 2021

Aug 13, 2021

BUY
$43.76 - $53.11 $3.36 Million - $4.08 Million
76,802 Added 8.9%
939,650 $41.4 Million
Q1 2021

May 18, 2021

BUY
$41.69 - $54.95 $168,302 - $221,833
4,037 Added 0.47%
862,848 $42.6 Million
Q4 2020

Feb 17, 2021

BUY
$41.16 - $47.47 $1.38 Million - $1.59 Million
33,482 Added 4.06%
858,811 $36.2 Million
Q3 2020

Nov 17, 2020

BUY
$43.36 - $53.53 $2.7 Million - $3.33 Million
62,226 Added 8.15%
825,329 $37.8 Million
Q2 2020

Aug 17, 2020

BUY
$46.37 - $57.58 $2.91 Million - $3.62 Million
62,785 Added 8.97%
763,103 $38.3 Million
Q1 2020

May 18, 2020

BUY
$40.22 - $62.0 $8.48 Million - $13.1 Million
210,933 Added 43.1%
700,318 $36 Million
Q4 2019

Feb 18, 2020

SELL
$57.95 - $66.61 $549,887 - $632,062
-9,489 Reduced 1.9%
489,385 $30.2 Million
Q3 2019

Nov 15, 2019

BUY
$60.08 - $88.17 $1.16 Million - $1.7 Million
19,298 Added 4.02%
498,874 $30 Million
Q2 2019

Aug 14, 2019

BUY
$81.3 - $97.35 $287,314 - $344,034
3,534 Added 0.74%
479,576 $40.5 Million
Q1 2019

May 15, 2019

SELL
$69.08 - $105.66 $4.06 Million - $6.21 Million
-58,783 Reduced 10.99%
476,042 $45.5 Million
Q4 2018

Feb 15, 2019

SELL
$65.41 - $84.65 $68,811 - $89,051
-1,052 Reduced 0.2%
534,825 $37.9 Million
Q4 2018

Feb 14, 2019

BUY
$65.41 - $84.65 $1.62 Million - $2.09 Million
24,691 Added 4.83%
535,877 $44.1 Million
Q3 2018

Nov 14, 2018

SELL
$85.46 - $126.37 $670,775 - $991,878
-7,849 Reduced 1.51%
511,186 $43.7 Million
Q2 2018

Aug 13, 2018

SELL
$81.85 - $120.51 $18.1 Million - $26.6 Million
-220,703 Reduced 29.84%
519,035 $60.2 Million
Q1 2018

May 14, 2018

SELL
$57.91 - $92.15 $7.36 Million - $11.7 Million
-127,032 Reduced 14.66%
739,738 $59.9 Million
Q4 2017

Feb 14, 2018

SELL
$45.65 - $59.37 $6.71 Million - $8.73 Million
-147,077 Reduced 14.51%
866,770 $50.9 Million
Q3 2017

Nov 14, 2017

BUY
$37.91 - $46.8 $38.4 Million - $47.4 Million
1,013,847
1,013,847 $47.4 Million

Others Institutions Holding ENTA

About ENANTA PHARMACEUTICALS INC


  • Ticker ENTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,724,900
  • Market Cap $188M
  • Description
  • Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...
More about ENTA
Track This Portfolio

Track Krensavage Asset Management, LLC Portfolio

Follow Krensavage Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Krensavage Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Krensavage Asset Management, LLC with notifications on news.